Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Assets (QoQ)Assets Growth (1y)Assets Growth (3y)Assets Growth (5y)Cash & Equivalents (QoQ)Cash & Equivalents Growth (1y)Cash & Equivalents Growth (3y)Cash & Equivalents Growth (5y)Cash from Operations (QoQ)Cash from Operations Growth (1y)Cash from Operations Growth (3y)Cash from Operations Growth (5y)EBIT (QoQ)EBIT Growth (1y)EBIT Growth (3y)EBIT Growth (5y)EBT (QoQ)EBT Growth (1y)EBT Growth (3y)EBT Growth (5y)EPS (Basic) (QoQ)EPS (Basic) Growth (1y)EPS (Basic) Growth (3y)EPS (Basic) Growth (5y)EPS (Weighted Average and Diluted) (QoQ)EPS (Weighted Average and Diluted) Growth (1y)EPS (Weighted Average and Diluted) Growth (3y)EPS (Weighted Average and Diluted) Growth (5y)Enterprise Value (QoQ)Enterprise Value Growth (1y)Enterprise Value Growth (3y)Enterprise Value Growth (5y)Free Cash Flow (QoQ)Free Cash Flow Growth (1y)Free Cash Flow Growth (3y)Free Cash Flow Growth (5y)Interest Coverage Ratio (QoQ)Interest Coverage Ratio Growth (1y)Net Cash Flow (QoQ)Net Cash Flow Growth (1y)Net Cash Flow Growth (3y)Net Cash Flow Growth (5y)Net Income (QoQ)Net Income Growth (1y)Net Income Growth (3y)Net Income Growth (5y)Net Income towards Common Stockholders (QoQ)Net Income towards Common Stockholders Growth (1y)Net Income towards Common Stockholders Growth (3y)Net Income towards Common Stockholders Growth (5y)Operating Income (QoQ)Operating Income Growth (1y)Operating Income Growth (3y)Operating Income Growth (5y)Profit After Tax (QoQ)Profit After Tax Growth (1y)Profit After Tax Growth (3y)Profit After Tax Growth (5y)Return on Assets Growth (1y)Return on Assets Growth (3y)Return on Assets Growth (5y)Return on Capital Employed (QoQ)Return on Capital Employed Growth (1y)Return on Equity (QoQ)Return on Equity Growth (1y)Return on Equity Growth (3y)Return on Equity Growth (5y)Return on Invested Capital (QoQ)Return on Invested Capital Growth (1y)Share-based Compensation (QoQ)Share-based Compensation Growth (1y)Share-based Compensation Growth (3y)Share-based Compensation Growth (5y)Shareholder's Equity (QoQ)Shareholder's Equity Growth (1y)Shareholder's Equity Growth (3y)Shareholder's Equity Growth (5y)Tax Rate (QoQ)
Income Statement
Others
Ratios

Akari Therapeutics (AKTX) Profit After Tax Growth (1y) (2015 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT Growth (1y) (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 65.80%
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 17.05%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -290.15%
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 59.59%
7 Evaxion A 62.56 Bn 62.54 Bn - -129.68%
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -10.08%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 1,228.66%
10 Revolution Medicines 32.39 Bn 32.39 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -290.15%
Dec 31, 2025 96.22%
Sep 30, 2025 -121.07%
Jun 30, 2025 74.93%
Mar 31, 2025 33.44%
Dec 31, 2024 -3,283.11%
Sep 30, 2024 -0.84%
Jun 30, 2024 -88.95%
Mar 31, 2024 -656.04%
Jun 30, 2023 29.58%
Mar 31, 2023 119.34%
Jun 30, 2022 -30.68%
Mar 31, 2022 11.34%
Dec 31, 2021 270.61%
Sep 30, 2021 -258.89%
Jun 30, 2021 41.58%
Mar 31, 2021 100.00%
Dec 31, 2020 13.03%
Sep 30, 2020 131.70%
Jun 30, 2020 -25.09%
Mar 31, 2020 -147,151,006.21%
Dec 31, 2019 -122.90%
Sep 30, 2019 19.80%
Jun 30, 2019 25.86%
Mar 31, 2019 290.15%
Dec 31, 2018 71.01%
Sep 30, 2018 65.37%
Jun 30, 2018 -2,406.81%
Mar 31, 2018 89.36%
Dec 31, 2017 -46.25%
Sep 30, 2017 -2,381.75%
Jun 30, 2017 95.04%
Mar 31, 2017 -321.54%
Dec 31, 2016 -228.02%
Sep 30, 2016 99.14%
Jun 30, 2016 -381.17%
Mar 31, 2016 -75.94%
Dec 31, 2015 681.09%
Sep 30, 2015 -21,741.93%
Jun 30, 2015 39.85%
Mar 31, 2015 2.48%